학술논문
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Document Type
Article
Author
San-Miguel, Jesús F; Hungria, Vânia T M; Yoon, Sung-Soo; Beksac, Meral; Dimopoulos, Meletios Athanasios; Elghandour, Ashraf; Jedrzejczak, Wieslaw Wiktor; Günther, Andreas; Nakorn, Thanyaphong Na; Siritanaratkul, Noppadol; Corradini, Paolo; Chuncharunee, Suporn; Lee, Je-Jung; Schlossman, Robert L; Shelekhova, Tatiana; Yong, Kwee; Tan, Daryl; Numbenjapon, Tontanai; Cavenagh, Jamie D; Hou, Jian; LeBlanc, Richard; Nahi, Hareth; Qiu, Lugui; Salwender, Hans; Pulini, Stefano; Moreau, Philippe; Warzocha, Krzysztof; White, Darrell; Bladé, Joan; Chen, WenMing; de la Rubia, Javier; Gimsing, Peter; Lonial, Sagar; Kaufman, Jonathan L; Ocio, Enrique M; Veskovski, Ljupco; Sohn, Sang Kyun; Wang, Ming-Chung; Lee, Jae Hoon; Einsele, Hermann; Sopala, Monika; Corrado, Claudia; Bengoudifa, Bourras-Rezki; Binlich, Florence; Richardson, Paul G
Source
In Lancet Oncology October 2014 15(11):1195-1206
Subject
Language
ISSN
1470-2045